On the heels of the September 17, 2014 FDA Advisory Committee meeting discussing the risks of testosterone, Ron Johnson of Schachter, Hendy & Johnson filed a class action lawsuit on behalf of those who paid for testosterone medications for "low T." As discussed during the FDA meeting, testosterone is not approved to treat "low T," also referred to as age-related hypogonadism, which may not even be a disease.
The class action was filed in conjunction with several other law firms in the nationwide personal injury litigation involving testosterone drugs before Judge Kennelly in the Northern District of Illinois (In Re: Testosterone Replacement Therapy Products Liability Litigation, Master Case Number 1:14-cv-01748, Specific Case Number 1:14-cv-8857). Ron is already co-lead counsel in this litigation.
Ron and his firm, Schachter, Hendy & Johnson, P.S.C., will now work diligently for those who paid for testosterone medications, like AndroGel, Axiron and Testim, based on allegedly deceptive marketing claims about "low T" and treating "low T" with testosterone.
As noted during the above-referenced FDA Advisory Committee meeting, the majority of men taking testosterone do so to treat a condition called "low T" or age-related hypogonadism. The FDA Advisory Committees were particularly disturbed by the fact that there is no evidence that testosterone treatment for "low T" confers any benefit. In fact, during the FDA Advisory Committee meeting it was noted that under modern standards testosterone could not be approved as a treatment for "low T."
The class action will focus on the allegedly fraudulent and illegal marketing practices involved in the promotion of testosterone medications and unbranded disease awareness campaigns by companies like Abbott, AbbVie, Actavis Pharma, Auxilium, Eli Lilly and Company, Endo Pharmaceuticals, and Watson Pharmaceuticals.
As co-lead counsel for the testosterone products liability litigation and as counsel in the class action, Ron will continue to fight for justice for those allegedly wronged by the manufacturers and marketers of testosterone.